Navigation Links
InterMune to Release Third Quarter Financial Results on November 3
Date:10/27/2011

BRISBANE, Calif., Oct. 27, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its third quarter 2011 financial results at the close of the U.S. markets on Thursday, November 3, 2011.  A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

Interested investors and others may participate in the conference call by dialing 888-567-5125 (U.S.) or 706-643-9223 (international), conference ID# 22885421.  A replay of the webcast and teleconference will be available on the company's website approximately three hours after the call. To access the live webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 855-859-2056 (U.S.) or 404-537-3406 (international), and entering the conference ID# 22885421.  

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.  In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved worldwide for IPF, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States.  Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biom
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. InterMune Announces Launch of Esbriet® (pirfenidone) in Germany
2. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
3. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
4. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune Reports Third Quarter 2010 Financial Results
7. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
8. InterMune to Release Second Quarter Financial Results on July 27
9. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
10. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
11. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015  Bayer HealthCare ... Administration (FDA) has accepted the company,s Biologics License ... VIII compound.  Bayer is seeking FDA approval of ... the treatment of hemophilia A in children and ... continually bringing new therapies to hemophilia A patients ...
(Date:3/4/2015)... Ga., March 4, 2015  Halyard Health, Inc. (NYSE: ... and provided its 2015 outlook and related key planning ... Halyard Health as we report our fourth quarter results, ... Chairman and CEO. "We executed a smooth separation from ... the spin-off. We delivered sales growth and margin improvement ...
(Date:3/4/2015)... March 4, 2015 Sanomedics , ... a medical technology company that focuses on providing ... that the Company,s subsidiary, Thermomedics, Inc. , has ... and Government Sales. LeBel will be reporting to ... Sales, and will be responsible for supporting assigned ...
Breaking Medicine Technology:FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 2Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 4Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 5Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 6Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 7Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 8Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 9Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 10Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 11Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 12Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 13Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 14Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 15Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 16Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 17Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 18Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 19Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 20Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 21Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 22Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 23Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 24Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 25Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 26Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 27Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 28Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 29Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 30Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 31Sanomedics Hires Scott W. LeBel as Director of Specialty and Government Sales 2Sanomedics Hires Scott W. LeBel as Director of Specialty and Government Sales 3
... , SAN MATEO, Calif., July 24 ... today the preliminary results of a short-term clinical study ... (PHN) following pretreatment with an FDA-approved topical anesthetic. As ... the U.S. Food and Drug Administration (FDA) requested the ...
... , , WISCONSIN ... of Wisconsin Cancer Center Riverview became the first medical facility ... of skin cancer. Located within Riverview Hospital, Wisconsin Rapids, the ... cancer patients with the FDA-cleared Axxent(R) Electronic Brachytherapy System from ...
Cached Medicine Technology:NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 2NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 3NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 4First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center 2First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center 3
(Date:3/5/2015)... 2015 Hoggan Scientific, a ... physical therapy, ergonomic force gauges, and ergoPAK ... engineering, and research applications, introduced the ... at http://www.HogganHealth.net . The new electronic ... professionals a handgrip muscle strength testing device ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 The Shaolin ... for Health and Wellness at Atlanta Shaolin Institute along ... 4350 Peachtree Industrial BLVD, Suite 500A, city of Peachtree ... Chan Foundation), which is a non-profit organization that promotes ... philosophy and medicine. , The seminar was well ...
(Date:3/4/2015)... Vegas, Nevada (PRWEB) March 04, 2015 ... is pleased to announce that they sell quality products ... Las Vegas, Nevada, this company obtains its merchandise from ... a known history of good performance. , Sleep apnea ... It is typically caused by reduced or restricted airflow. ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Imagine No Malaria’s ... the Care2 Innovator Award , an honor given to ... today at the Nonprofit Technology Conference (NTC15) in ... Tarrytown United Methodist Church in Austin, was on hand for ... for Imagine No Malaria. , Imagine No Malaria was one ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Ultraman Florida ... 6.2 mile swim, 261.4 mile bike, and 52.4 mile ... total time of 24:45:45. , "This race was awesome ... my wonderful team and sponsors for supporting me through ... Florida 2015 had a total of 40 select participants ...
Breaking Medicine News(10 mins):Health News:New Handgrip Strength Tester Receives Rave Reviews At Physical Therapy Conference 2Health News:Top Martial Arts Master Wu Bin of China, Has Successfully Conducted a Time-Honored Kung Fu Seminar for Health & Wellness at Shaolin Institute, Atlanta, GA 2Health News:Top Martial Arts Master Wu Bin of China, Has Successfully Conducted a Time-Honored Kung Fu Seminar for Health & Wellness at Shaolin Institute, Atlanta, GA 3Health News:Sleep Apnea Machines CPAP and BiPap Machines Now Available for Sale 2Health News:Imagine No Malaria Receives Care2 Innovator Award 2Health News:Imagine No Malaria Receives Care2 Innovator Award 3Health News:Living Fuel Champion Christian Isakson Finishes Second In UltraMan Florida Test of Endurance 2
... today,announced that Noel Obourn, former chief sales officer ... president of financial,planning and analysis at Netflix, Inc., ... joins effective today as executive,vice president and head ... 18 and joins as senior vice president and ...
... for cross-border prevention, treatment programs , , WEDNESDAY, July 30 ... fourfold for male injection drug users who were deported ... in the Mexican border city, a new study reports. ... 5 at the International AIDS Conference in Mexico City, ...
... fat cells, may play a pivotal and counterintuitive role ... new study accepted for publication in the Journal ... people lose weight, the concentration level of adiponectin in ... has been associated with lower occurrence of diabetes and ...
... Premier Professional Online Medical Resource as ... ... Doctor,s Channel, (http://www.thedoctorschannel.com ), today announced the appointment of Jaime,Landman, ... Editor. Hailed by CNBC as the "educational,YouTube" for doctors, The ...
... STERIS Corporation,(NYSE: STE ) today announced financial ... 2008. Fiscal 2009 first quarter revenues increased,11% to $311.6 ... of,fiscal 2008, primarily driven by double digit revenue growth ... income was $25.5 million, or $0.43 per,diluted share, compared ...
... Unit-of-Use prescription compounding kits to its ... WOBURN, Mass., July 30 CutisPharma, ... prescription compounding, announced a,partnership with Rite Aid ... make its,innovative FIRST(R) Unit-of-Use Prescription Compounding Kits ...
Cached Medicine News:Health News:Extend Health, Inc. Adds Veteran Leadership to Management Team 2Health News:Deportation Tied to Higher HIV Risk for Men Injecting Drugs 2Health News:Deportation Tied to Higher HIV Risk for Men Injecting Drugs 3Health News:Protein made by fat cells may increase risk of heart attack in older adults 2Health News:The Doctor's Channel Adds Esteemed Director of Minimally Invasive Urology at Columbia University to Editorial Team 2Health News:The Doctor's Channel Adds Esteemed Director of Minimally Invasive Urology at Columbia University to Editorial Team 3Health News:STERIS Corporation Announces Fiscal 2009 First Quarter Results 2Health News:STERIS Corporation Announces Fiscal 2009 First Quarter Results 3Health News:STERIS Corporation Announces Fiscal 2009 First Quarter Results 4Health News:STERIS Corporation Announces Fiscal 2009 First Quarter Results 5Health News:STERIS Corporation Announces Fiscal 2009 First Quarter Results 6Health News:STERIS Corporation Announces Fiscal 2009 First Quarter Results 7Health News:STERIS Corporation Announces Fiscal 2009 First Quarter Results 8Health News:STERIS Corporation Announces Fiscal 2009 First Quarter Results 9Health News:STERIS Corporation Announces Fiscal 2009 First Quarter Results 10Health News:CutisPharma Announces Strategic Collaboration with Rite Aid Corporation 2Health News:CutisPharma Announces Strategic Collaboration with Rite Aid Corporation 3
The FLEXI-CUT Directional Debulking System is Abbott Vascular's latest atherectomy catheter designed to enhance performance and ease-of-use....
The New Vantage Plus. The PLUS gives you: ,P Premium intelligent optics ,L Lighter weight and brighter images ,U Unique wireless patented technology ,S Smaller and more compact size ...
... Simple, compact, and easy to use, the ... technology to every OR. The business model ... hospitals and surgeons with the most flexible ... facilities. ,The z-boxTM is designed to run ...
NOW Legionella is an immunochromatographic membrane assay to detect Legionella pneumophila serogroup 1 soluble antigen in human urine....
Medicine Products: